RPN-001 Phase 2 fertility readout
ReproNovo lists a US Phase 2 trial of leflutrozole in men with low sperm count and low testosterone, NCT06993155. The oral aromatase inhibitor aims to rebalance reproductive hormones.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Private-company classification explicitly supported by ReproNovo’s October 5, 2026 announcement; recheck before activation.
- Primary endpoint and statistical hierarchy must be copied from the live protocol before an efficacy-success market is written.
- Research candidate, not a live market, clinical probability, company equity or access to private shares.
Primary evidence
Phase 2 readout — date unconfirmed
Company context
An official company source identifies the company as privately held. This is source-reported context, not independent legal-registry verification; recheck ownership, listing and acquisition status before any market listing.
Potential outcome market
Will ReproNovo publicly report the prespecified primary analysis of RPN-001 trial NCT06993155 by the market deadline?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.